TransMedics Group (NASDAQ:TMDX) PT Raised to $169.00

TransMedics Group (NASDAQ:TMDX) had its price objective upped by Canaccord Genuity Group from $117.00 to $169.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on TMDX. Piper Sandler increased their target price on shares of TransMedics Group from $120.00 to $170.00 and gave the stock an overweight rating in a research report on Monday, July 15th. Stephens assumed coverage on TransMedics Group in a research report on Tuesday, June 4th. They set an overweight rating and a $151.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on TransMedics Group from $105.00 to $127.00 and gave the company an overweight rating in a research report on Wednesday, May 1st. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They set an overweight rating and a $161.00 target price on the stock. Finally, Morgan Stanley lifted their price target on TransMedics Group from $104.00 to $145.00 and gave the company an equal weight rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, TransMedics Group has an average rating of Moderate Buy and a consensus price target of $166.88.

TransMedics Group Stock Down 0.9 %

Shares of TMDX opened at $150.10 on Thursday. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The company has a 50-day moving average price of $144.02 and a two-hundred day moving average price of $111.51. The stock has a market cap of $4.94 billion, a price-to-earnings ratio of -441.47 and a beta of 1.99. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $171.98.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 17.37% and a net margin of 0.84%. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the company earned ($0.03) EPS. TransMedics Group’s revenue was up 117.7% on a year-over-year basis. Equities analysts predict that TransMedics Group will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a filing with the SEC, which is available through this link. In other TransMedics Group news, CFO Stephen Gordon sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $141.40, for a total value of $2,828,000.00. Following the completion of the transaction, the chief financial officer now directly owns 21,299 shares in the company, valued at $3,011,678.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,948,714.31. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,120 shares of company stock worth $7,401,345. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in TransMedics Group by 3.9% in the 2nd quarter. Rhumbline Advisers now owns 47,645 shares of the company’s stock valued at $7,176,000 after acquiring an additional 1,783 shares during the period. Natixis Advisors LLC bought a new position in shares of TransMedics Group during the second quarter worth approximately $9,059,000. nVerses Capital LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $241,000. Commonwealth Equity Services LLC boosted its stake in TransMedics Group by 62.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 6,497 shares of the company’s stock valued at $979,000 after purchasing an additional 2,491 shares during the period. Finally, Matisse Capital acquired a new position in TransMedics Group in the 2nd quarter valued at $452,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.